Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 9/20 | 0.59 |
| ▸ | SORT1 | Q99523 | 9/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311794 | 0.81 | GRN (0.66) | GRNSORT1KDM4ENPC1CNR1 | |
| SCHEMBL2933232 | 0.77 | GRN (0.61) | GRNSORT1KDM4ENPC1CNR1 | |
| SCHEMBL13056666 | 0.76 | GRN (0.64) | GRNSORT1KDM4ENPC1CNR1 | |
| SCHEMBL4310512 | 0.76 | GRN (0.59) | GRNSORT1KDM4ENPC1CNR1 | |
| SCHEMBL574145 | 0.76 | GRN (0.64) | GRNSORT1KDM4ENPC1CNR1 | |
| SCHEMBL19128583 | 0.76 | GRN (0.59) | GRNSORT1KDM4ENPC1CNR1 | |
| SCHEMBL12847484 | 0.76 | GRN (0.35) | GRNSORT1KDM4ENPC1CNR1 | |
| SCHEMBL15888010 | 0.75 | MAPK14 (0.44) | GRNSORT1CNR1CNR2MAPT | |
| SCHEMBL12789850 | 0.75 | GRN (0.35) | GRNSORT1KDM4ENPC1CNR1 | |
| SCHEMBL4421820 | 0.75 | GRN (0.58) | GRNSORT1KDM4ENPC1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285805-B1 | ARYL-QUINOLYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-07-23 | — | — | EP | disclosed |
| US-8383816-B2 | Aryl-quinolyl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| CN-102066371-A | Aryl-quinolyl compounds and their use | CANCER REC TECH LTD | 2011-05-18 | — | — | CN | disclosed |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| EP-2285805-A1 | ARYL-QUINOLYL COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009130487-A1 | ARYL-QUINOLYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | BRAF, NRAS, ARAF | GRN 3128/4885SORT1 3257/4885KDM4E 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.